Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin

• US 20080004212A1
• Filed: 04/21/2006
• Published: 01/03/2008
• Est. Priority Date: 12/07/2004
• Status: Abandoned Application

• Current Assignee: Gtc-Biotherapeutics Incorporated
• Original Assignee: Gtc-Biotherapeutics Incorporated
• Inventors: Jourdain, Merce, Echelard, Yann, Pattou, Francois
• Application Number:
  US11/408,659
• Publication Number:
  US 20080004212A1
• Time in Patent Office: Days
• US Class Current: 514/8
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

The use of antithrombin to improve the therapeutic efficacy of cell and organ transplantation.

Claims

1. (canceled)

4. The protein of claim 1, wherein said antithrombin is human antithrombin.

5. The protein of claim 1, wherein said antithrombin is a recombinant transgenic protein produced in an ungulate.

8. A recombinant protein as recited in claim 1 wherein the mammal is a human. encoding the polypeptide.

2. An antithrombin protein delivered in an amount sufficient to improve the therapeutic efficacy of a cell or tissue transplant in an animal.

3. The protein of claim 2, wherein said antithrombin is a transgenic protein and is the product of a contiguous coding sequence of DNA.

6-7. -7. (canceled)

9-16. -16. (canceled)